NASDAQ:WGS | Free Cash Flow | GeneDx Holdings Corp.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2019-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$32.41M$6.45M-$38.86M
2025-12-31-$3.09M$4.35M-$7.44M
2025-03-31$10.18M$6.13M$4.05M
2024-12-31-$3.18M$3.05M-$6.23M-114.62%
2024-03-31-$16.41M$443,000.00-$16.86M
2023-12-31-$29.86M$2.38M-$32.23M
2023-03-31-$55.56M$0.00-$55.56M
2022-12-31-$64.65M$2.17M-$66.82M
2022-03-31-$81.49M$1.38M-$82.87M
2021-12-31-$51.99M$5.06M-$57.04M
2021-03-31-$42.21M$2.08M-$44.28M
2020-12-31-$18.33M$6.78M-$25.12M
2020-09-30-$365,808.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31$33.28M$19.02M$14.26M
2024-12-31-$28.5M$5.49M-$33.99M
2023-12-31-$180.15M$5.25M-$185.4M
2022-12-31-$319.16M$7.16M-$326.31M
2021-12-31-$190.43M$9.4M-$199.83M
2020-12-31-$93.13M$24.09M-$117.22M
2019-12-31-$18.73M$11.92M-$30.65M

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.